Additional staining of primary tumour samples for mutations in the tumour suppressor TRP53 showed no marked differences in frequency of tumours with TRP53 mutations between Eμ-Myc/dCas9a-SAMKI/+/sgBcl-2 and control lymphomas (Supplementary Fig. 7b), and is in concordance with human DHL studies in which TP53 mutations have also been reported34. This evidence concerns the gene TP53 and neoplasm.